I now have comprehensive information to give a thorough answer. Let me synthesize this.
Social Anxiety Disorder (SAD) — Also Called Social Phobia
This patient's presentation is a textbook case. He is in administration (a position requiring group interaction), but when required to speak in a group, he experiences palpitations (racing heart), sweating, and throat constriction — the classic autonomic arousal response of social anxiety disorder.
What Is It?
Social Anxiety Disorder (SAD) is a marked and persistent fear of one or more social or performance situations in which the individual fears scrutiny by others, or fears doing something embarrassing. The core fear is of negative evaluation, embarrassment, or social rejection.
The anxiety in your patient is specifically performance-type SAD — triggered by public speaking/group settings — which is extremely common in professionals whose roles require group interaction.
"Persons with social anxiety disorder are fearful of embarrassing themselves in social situations (i.e., social gatherings, oral presentations, meeting new people)."
— Kaplan and Sadock's Synopsis of Psychiatry
Why These Physical Symptoms?
The physical symptoms (tachycardia, sweating, throat tightness) result from autonomic nervous system arousal — specifically sympathetic activation ("fight-or-flight") triggered by perceived social threat. Neurobiologically, this stems from:
- Hyperresponsive amygdala — heightened activation to social stimuli, even at low thresholds
- Weaker frontolimbic connectivity — reduced prefrontal regulation of emotional reactivity
- Heightened insula activation — contributing to the visceral/somatic sensations
"Such symptom provocation studies using both PET and fMRI consistently demonstrate heightened amygdala activity in patients with SAD compared to healthy controls."
— Kaplan & Sadock's Comprehensive Textbook of Psychiatry
DSM-5 Diagnostic Criteria (Key Points)
| Feature | This Patient |
|---|
| Fear of scrutiny in social situations | ✅ Group speaking |
| Fear that others will notice anxiety | ✅ Visible sweating, voice changes |
| Avoidance behaviors | ✅ Likely avoids group meetings |
| Fear out of proportion to actual risk | ✅ |
| Duration ≥ 6 months | Need to confirm |
| Not explained by another disorder | Need to rule out |
Differential Diagnosis
- Panic disorder — differentiated by spontaneous attacks not limited to social situations
- Generalized anxiety disorder — broader, free-floating anxiety, not situation-specific
- Specific phobia — fear of an object/situation itself, not of being embarrassed within it
- Performance anxiety (normal) — must cross the threshold of clinically significant distress or impairment
Treatment
First-Line: Psychotherapy
Cognitive-Behavioral Therapy (CBT) — specifically individual CBT — has the largest effect size of all treatments.
Key CBT components:
| Component | What It Does |
|---|
| Psychoeducation | Corrects distorted beliefs about social threat |
| Cognitive restructuring | Challenges catastrophic thoughts ("everyone will laugh at me") |
| Behavioral exposure | Gradual, systematic exposure to feared social situations |
| Somatic management | Breathing retraining, relaxation training to address the tachycardia/sweating |
| Safety behavior elimination | Removes avoidance strategies that maintain the anxiety |
| Social skills training | Builds confidence in group settings |
"Individual CBT had the largest effect size (greater than group CBT and other treatments) and was significantly more effective than psychodynamic therapy, supportive therapy, or mindfulness."
— Kaplan & Sadock's Comprehensive Textbook of Psychiatry
Cognitive-Behavioral Group Therapy (CBGT) (Heimberg's model) is also well-validated — with the added benefit that the group itself serves as an exposure environment.
First-Line: Pharmacotherapy
SSRIs are the first-line pharmacological treatment:
- Paroxetine, sertraline, fluvoxamine, escitalopram
- Also SNRIs (venlafaxine)
Beta-blockers (propranolol, atenolol) — specifically useful for performance-type SAD, as in this patient. They blunt the peripheral sympathetic response (tachycardia, tremor, sweating) and are commonly used situationally (e.g., taken 1 hour before a presentation).
Benzodiazepines (e.g., clonazepam) — short-term or adjunctive use; alprazolam has shown benefit but carries dependence risk.
MAOIs (phenelzine) — historically effective (64% response rate vs. 20% placebo in trials) but reserved for refractory cases due to dietary restrictions and side-effect burden.
"Given SSRIs' tolerability and safety, they should remain the first-line treatment for social anxiety disorder."
— Kaplan & Sadock's Comprehensive Textbook of Psychiatry
Combined Therapy
Evidence supports combined CBT + pharmacotherapy for moderate-to-severe cases. One major RCT found combined phenelzine + CBGT achieved remission in 59.4% vs. ~20% for either alone.
Practical Points for This Patient
- Confirm duration ≥ 6 months and functional impairment at work
- Rule out medical causes of tachycardia (hyperthyroidism, cardiac arrhythmia)
- Start with individual CBT — this has the best evidence and most durable results
- Add an SSRI if CBT alone is insufficient or severity is moderate-high
- Propranolol PRN can be offered as a short-term measure for immediate speaking situations while longer-term treatment takes effect
- Internet-based CBT has shown good efficacy and may be more accessible given his work schedule
Sources: Kaplan and Sadock's Synopsis of Psychiatry; Kaplan & Sadock's Comprehensive Textbook of Psychiatry